Physician profile
C Keith Chitty
NPI 1609983196
$3,544.65
in general payments reported to CMS, 2019-2025
31 companies · $462 in 2025
The $462 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $144 · 2021: $566 · 2022: $641 · 2023: $338 · 2024: $945 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $552.05 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $436.63 | 2019-2024 | Jornay Pm |
| Corium, LLC | $385.27 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $356.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $279.32 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Adlon Therapeutics L.P. | $217.74 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.92 | 2020-2022 | |
| Pfizer INC. | $206.64 | 2019-2025 | |
| Cranial Technologies, INC | $188.19 | 2019-2025 | Doc Band |
| Kaleo, INC. | $74.49 | 2019-2023 | Auvi-Q |
| Seqirus USA INC | $66.19 | 2021-2024 | Flucelvax |
| Neos Therapeutics, LP | $65.35 | 2021-2022 | |
| Genentech USA, INC. | $63.98 | 2019-2021 | |
| Quidel Corporation | $47.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $39.56 | 2024 | Flumist Quadrivalent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $35.35 | 2023-2025 | Ycanth |
| Sobi, INC | $33.43 | 2021-2022 | |
| Shire North American Group INC | $32.73 | 2019 | |
| Collegium Pharmaceutical, INC. | $31.25 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $30.69 | 2025 | |
| Tris Pharma INC | $29.06 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $21.85 | 2025 | Neffy |
| Ns Pharma, INC. | $18.72 | 2023 | Viltepso |
| Sanofi-Aventis U.S. LLC | $18.29 | 2024 | |
| Biomerieux INC | $17.51 | 2025 | Biofire Spotfire Control Station |
| Biogen, INC. | $16.81 | 2021 | |
| Roche Diagnostics Corporation | $16.01 | 2019 | |
| Phadia US INC. | $15.13 | 2025 | Immunocap |
| Novo Nordisk INC | $14.89 | 2024 | Wegovy |
| Glaxosmithkline, LLC. | $14.08 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw C Chitty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.